A Phase 1/2 interventional study of Dexbrompheniramine and Temozolomide in High Grade Glioma, Glioblastoma and Gliosarcoma, sponsored by University of Nebraska. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Nebraska · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.
Among the 112 studies testing temozolomide in Glioma, this one is the 51st largest by planned enrollment of the 104 interventional ones that give a count, is one of 2 that started in 2027, is one of 17 in phase 1/2, reaches primary completion later than 16 of the 17 other live ones, and was the 106th registered.
1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 12+
Mayo Clinic · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18–85
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 68 · Phase 3 5 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 41 is above the median of 32 across 1,078 interventional studies indexed under Glioma.
Median enrollment 41 across the 104 interventional studies. Of the 80 that completed or were terminated, 33 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 112 have an industry lead sponsor. The 10 most frequent:
University of Nebraska is the lead sponsor of 496 studies on the registry; 66 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.
University of Nebraska has 6 studies filed under Glioma — fewer than ten, so there is no comparison to draw.
5 of the studies testing temozolomide in Glioma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT06258018Armando Santoro, MDNiraparib and Temozolomide in Patients Glioblastoma | 2026-12 |
| NCT05188508Memorial Sloan Kettering Cancer CenterPembrolizumab, Olaparib, and Temozolomide for People With Glioma | 2027-01 |
| NCT05030298Mayo ClinicPreoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial | 2027-03-15 |
| NCT07599371The First Affiliated Hospital of Zhengzhou UniversityA Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma | 2027-10-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies testing temozolomide in Glioma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been previously treated with standard of care chemoradiation therapy and 2) determine the efficacy of the combination therapy in adults with glioblastoma who progressed during the first six cycles of adjuvant standard dose temozolomide.
The main questions it aims to answer are:
Participants will take dexbrompheniramine and temozolomide every day at night.
Inclusion Criteria (Phase I)
Inclusion Criteria (Phase II)
1. Proven glioblastoma/gliosarcoma (2021 WHO criteria) that progressed after standard chemoradiation within the first six cycles of adjuvant TMZ.
Inclusion Criteria (Both Phases)
Adequate organ function:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive daily dexbrompheniramine (either 4 mg, 6 mg, or 8 mg) together with 50mg/m2/day temozolomide for up to one year or until progression or intolerance.
Drug: Dexbrompheniramine · Drug: Temozolomide
Participants receive daily dexbrompheniramine at the recommended phase 2 dose together with 50mg/m2/day temozolomide for up to one year or until progression or intolerance.
Drug: Dexbrompheniramine · Drug: Temozolomide
Antihistamine, HRH1 antagonist
Also known as: ALA-HIST-IR
DNA Alkylating Agent
Also known as: Temodar
Safety and RP2D of Combination Therapy
Evaluate toxicity and determine the recommended dose of dexbrompheniramine with metronomic temozolomide in subjects with recurrent grade 3 and grade 4 glioma.
Time frame: 24 months
Efficacy (PFS) of Combination Therapy
Evaluate efficacy (PFS) of the recommended dose of dexbrompheniramine with metronomic temozolomide in subjects with glioblastoma/gliosarcoma who progress during their first six cycles of adjuvant standard dose temozolomide. (Phase II)
Time frame: 48 months
To measure blood concentration of dexbrompheniramine with temozolomide
Characterize pharmacokinetics (PK) of dexbrompheniramine with temozolomide in combination (Phase I) Population PK analyses will be used to estimate PK parameters for subjects with available PK sample collection, as means, SDs, medians, minimums, and maximums.
Time frame: 24 months
Efficacy (PFS, OS, TTF)
Estimate progression free survival at 6 and 12 months, overall survival, and time to treatment failure (Both Phases).
Time frame: 48 months
Examine quality of life changes using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30.)
Examine Quality of Life (QOL) using EORTC QLQ-C30 (Both Phases). EORTC QLQ-C30 will be summarized descriptively at each time point measured with mean, SD, median, and ranges in the intent-to-treat analysis set. Changes within subject over time will be graphically displayed with profile plots.
Time frame: 48 months
Tumor Response (RANO).
Measure tumor response to treatment using RANO criteria (Both Phases)
Time frame: 48 months
Correlative Studies- Next Generation Sequencing (NGS)
Correlate molecular profiles NGS and HRH1 expression with treatment outcomes. We will correlate molecular profiles (next generation sequencing) with tumor response as sample size allows, by dose level and overall. We will determine if changes in molecular profiles are associated with response using Kruskal-Wallis test or Wilcoxon rank sum test depending on the number of response categories. Expression levels will be correlated with each other using scatterplots and Spearman correlation. Mutational status will be assessed with frequency and percentage for each response category. Fisher's exact test will be used to determine whether there is an association between common mutations and response.
Time frame: 48 months
Correlative Studies- MGMT Status
Correlate molecular profiles MGM and HRH1 expression with treatment outcomes. We will correlate molecular profiles (MGMT) with tumor response as sample size allows, by dose level and overall. We will determine if changes in molecular profiles are associated with response using Kruskal-Wallis test or Wilcoxon rank sum test depending on the number of response categories. Expression levels will be correlated with each other using scatterplots and Spearman correlation. Mutational status will be assessed with frequency and percentage for each response category. Fisher's exact test will be used to determine whether there is an association between common mutations and response.
Time frame: 48 months
Biological Changes-Exosome HRH1
Evaluate changes in exosome HRH1 during treatment.
Time frame: 48 months
Biological Changes-Ki67cells
Evaluate changes in Ki67 during treatment. The focused analysis will be done on the Ki67 cells in pre and post D-Brom dosage and levels associated with OS and PFS. Specifically, the Kaplan-Meier method will estimate OS and PFS distributions by median levels of Ki67 cells, pre-Brom dosage, with comparisons using the log-rank test. Cox regression will also consider Ki67 cellsas a time varying covariate (using the 3 time points collected) of OS and PFS. These analyses will be done by dose level and separately for the window of opportunity study (if sample size allows).
Time frame: 48 months
Biological Changes-CD8
Evaluate changes in CD8 during treatment. The focused analysis will be done on the CD8 cells in pre and post D-Brom dosage and levels associated with OS and PFS. Specifically, the Kaplan-Meier method will estimate OS and PFS distributions by median levels of CD8 cells, pre-Brom dosage, with comparisons using the log-rank test. Cox regression will also consider CD8 cells as a time varying covariate (using the 3 time points collected) of OS and PFS. These analyses will be done by dose level and separately for the window of opportunity study (if sample size allows).
Time frame: 48 months
Biological Changes-T Cells
Evaluate changes in T-Cells during treatment. The focused analysis will be done on the T cells in pre and post D-Brom dosage and levels associated with OS and PFS. Specifically, the Kaplan-Meier method will estimate OS and PFS distributions by median levels of T cells, pre-Brom dosage, with comparisons using the log-rank test. Cox regression will also consider T cells as a time varying covariate (using the 3 time points collected) of OS and PFS. These analyses will be done by dose level and separately for the window of opportunity study (if sample size allows).
Time frame: 48 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for Jun 2030, 36 months later.
Of 45 non-industry phase 1/2 interventional studies under Glioma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 104. This study's planned 36 months is below that.
Counting every sponsor, half of 71 studies reached it within 66 months; a quarter within 48 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide